Monday 22 May 2017

Stakeholders validate National Strategic Health Development Plan for cohesive implementation framework

Abuja 18 May 2017 - This week, stakeholders converged in Abuja from 15-16 May, 2017 to validate Nigeria’s draft National Strategic Health Development Plan Framework II (NSHDP II). The framework will guide government at both states and federal levels to develop specific plans that will feed into the overall Health Strategic Plan. The Minister of Health, Professor Isaac Adewole, in his address encouraged states to develop state-specific plans using NSHDP II framework as a guide to achieve coherence between local operational plans and the national strategic plan. “For the NSHDP II to be effective, it must be linked to sub-national operational plans, at the state or local government level”, Professor Adewole emphasized. The NSHDP II framework founded on the eight pillars of the health system, links health service delivery with system strengthening which include: Leadership and Governance for Health; Health Service Delivery; Human Resources for Health; Financing for Health; National Health Management Information System; Partnerships for Health; Community Participation and Ownership; and Research for Health. World Health Organization (WHO) actively supported the validation of NSHDP II framework, as part of the larger process that aims to align country priorities with the real health needs of the population so that people across the country will have access to quality health care, and live longer, healthier lives. It will also generate buy-in across different tiers of government, health and development partners, civil society and the private sector in order to optimize the utilization of available resources for health. However, Dr Wondimagegnehu Alemu the WHO country Representative to Nigeria, reminded participants at the workshop that the implementation of the NSHDP II will require ownership, oversight, resourcing and accountability. He stressed that WHO will continue to support the NHSDP II implementation process by providing appropriate technical assistance and platforms for policy dialogue as well as ensuring evidence based costing. The validation workshop was attended by the Minister of Health, the Minister of State for Health, Commissioners of Health from all 36 States, Development Partners and other stakeholders.

Major research funders and international NGOs to implement WHO standards on reporting clinical trial results

Major research funders and international NGOs to implement WHO standards on reporting clinical trial results News release 18 MAY 2017 | GENEVA - Some of the world’s largest funders of medical research and international non-governmental organizations today agreed on new standards that will require all clinical trials they fund or support to be registered and the results disclosed publicly. In a joint statement, the Indian Council of Medical Research, the Norwegian Research Council, the UK Medical Research Council, Médecins Sans Frontières and Epicentre (its research arm), PATH, the Coalition for Epidemic Preparedness Innovations (CEPI), Institut Pasteur, the Bill & Melinda Gates Foundation, and the Wellcome Trust agreed to develop and implement policies within the next 12 months that require all trials they fund, co-fund, sponsor or support to be registered in a publicly-available registry. They also agreed that all results would be disclosed within specified timeframes on the registry and/or by publication in a scientific journal. Today, about 50% of clinical trials go unreported, according to several studies, often because the results are negative. These unreported trial results leave an incomplete and potentially misleading picture of the risks and benefits of vaccines, drugs and medical devices, and can lead to use of suboptimal or even harmful products. "Research funders are making a strong statement that there will be no more excuses on why some clinical trials remain unreported long after they have completed," said Dr Marie-Paule Kieny, Assistant Director-General for Health Systems and Innovation at WHO. The signatories to the statement also agreed to monitor compliance with registration requirements and to endorse the development of systems to monitor results reporting. "We need timely clinical trial results to inform clinical care practices as well as make decisions about allocation of resources for future research," said Dr Soumya Swaminathan, Director-General of the Indian Council of Medical Research. "We welcome the agreement of international standards for reporting timeframes that everyone can work towards." In 2015 WHO published its position on public disclosure of results from clinical trials, which defines timeframes within which results should be reported, and calls for older unpublished trials to be reported. That position builds on the World Medical Association’s Declaration of Helsinki in 2013. Today’s agreement by some of the world’s major research funders and international NGOs will mean the ethical principles described in both statements will now be enforced in thousands of trials every year. "Requiring summary results of clinical trials to be made freely available through open access registries within 12 months of study completion is good for both science and society," said Dr Jeremy Farrar, Director of the Wellcome Trust. "Not only will this help ensure that these research findings are more discoverable, but it will also reduce reporting biases, which currently favour publication of trials which have a positive outcome. Today’s statement is in line with Wellcome’s broader ambition to make all research outputs which arise from our funding more findable, accessible, and re-usable." Most of these trials and their results will be accessible via WHO’s International Clinical Trials Registry Platform, a unique global database of clinical trials that compiles data from 17 registries around the world, including the United States of America’s clinicaltrials.gov, the European Union’s Clinical Trials Register, the Chinese and Indian Clinical Trial Registries and many others. International Clinical Trials Registry Platform "We fully support this statement and look forward to working towards increasing the availability of results from clinical trials,” said Dr John-Arne Røttingen, Chief Executive of the Research Council of Norway. “The public disclosure of results from clinical trials will improve resource

Seventieth World Health Assembly


Seventieth World Health Assembly